Who is eligible for clinical trial NCT06003426?

Participants must meet protocol criteria for Idiopathic Pulmonary Fibrosis. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06003426 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-20

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis (NCT06003426)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (5 items).

Location: Local Institution - 0189 — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Subjects with IPF aged ≥ 40 years at the time of signing the informed consent.
Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia.
If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.
If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.
Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test.
Men who are sexually active with women of childbearing potential agree to use male barrier contraception.

Usually NOT eligible if any of the following apply:

Exclusion Criteria
History of stroke or transient ischemic attack within 3 months prior to screening.
Participants who exhibit symptoms of heart failure at rest.
Participants who have a current malignancy or a previous malignancy with less than 2 years free of recurrence or a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.
Other protocol-defined Inclusion/Exclusion criteria apply

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (390 Sites)

Local Institution - 0189 — Birmingham, Alabama
Local Institution - 0361 — Phoenix, Arizona
Local Institution - 0396 — La Jolla, California
Local Institution - 0193 — Los Angeles, California
Local Institution - 0398 — Los Angeles, California
Local Institution - 0389 — Orange, California
Local Institution - 0405 — Sacramento, California
Local Institution - 0185 — San Francisco, California
Local Institution - 0186 — Stanford, California
Local Institution - 0363 — Aurora, Colorado
Local Institution - 0194 — Denver, Colorado
Local Institution - 0175 — New Haven, Connecticut
Local Institution - 0151 — Newark, Delaware
Local Institution - 0367 — Washington D.C., District of Columbia
Local Institution - 0101 — Brandon, Florida
Local Institution - 0436 — Clearwater, Florida
Local Institution - 0425 — DeBary, Florida
Local Institution - 0079 — Gainesville, Florida
Local Institution - 0352 — Hialeah, Florida
Local Institution - 0370 — Kissimmee, Florida
Local Institution - 0502 — Leesburg, Florida
Local Institution - 0153 — Loxahatchee Groves, Florida
Local Institution - 0187 — Ocala, Florida
Local Institution - 0418 — Pensacola, Florida
Local Institution - 0206 — St. Petersburg, Florida

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗